Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 4/20 | 0.72 |
| ▸ | PKN1 | Q16512 | 4/20 | 0.72 |
| ▸ | PAK4 | O96013 | 3/20 | 0.72 |
| ▸ | PAK3 | O75914 | 3/20 | 0.72 |
| ▸ | PAK2 | Q13177 | 3/20 | 0.72 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.72 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.72 |
| ▸ | WEE1 | P30291 | 1/20 | 0.51 |
| ▸ | TNK2 | Q07912 | 9/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.48 |
| ▸ | JAK3 | P52333 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15035162 | 0.89 | PAK1 (0.70) | PAK1PKN1PAK4PAK3PAK2 | |
| SCHEMBL14824791 | 0.88 | PAK1 (0.69) | PAK1PKN1PAK4PAK3PAK2 | |
| SCHEMBL14824760 | 0.87 | PAK1 (0.67) | PAK1PKN1PAK4PAK3PAK2 | |
| SCHEMBL15030339 | 0.86 | PAK1 (0.72) | PAK1PKN1PAK4PAK3PAK2 | |
| SCHEMBL10192789 | 0.84 | PAK1 (1.00) | PAK1PKN1PAK4PAK3PAK2 | |
| SCHEMBL29504158 | 0.84 | PAK1 (1.00) | PAK1PKN1PAK4PAK3PAK2 | |
| SCHEMBL31110556 | 0.84 | PAK1 (1.00) | PAK1PKN1PAK4PAK3PAK2 | |
| SCHEMBL15035152 | 0.83 | PAK1 (0.70) | PAK1PKN1PAK4PAK3PAK2 | |
| SCHEMBL14824794 | 0.82 | PAK1 (0.69) | PAK1PKN1PAK4PAK3PAK2 | |
| SCHEMBL1680969 | 0.82 | PAK1 (0.85) | PAK1PKN1PAK4PAK3PAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2013086451-A2 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | PAK1 4/4885PKN1 326/4885PAK4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.